| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397 |
| filingDate |
2008-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010537966-A |
| titleOfInvention |
Pharmaceutical formulation for sustained release |
| abstract |
Compounds as the active ingredient Ph (3-Cl) (5 -OCHF 2) - (R) CH (OH) C (O) - (S) pharmaceutically acceptable salts of Aze-Pab (OMe) or said compound [E.g., sulfonate salts (e.g., benzene sulfonic acid (besylate) salts)]; and pharmaceutically acceptable diluents or carriers; and metabolized by other concomitantly administered drugs (especially by CYP-450 enzymes) Sustained release pharmaceutical formulations for use in providing anti-thrombotic therapeutic effects while suppressing drug-drug interactions with the drug. [Selection] Figure 3 |
| priorityDate |
2007-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |